PET scanner Caremibrain

for cranial scintigraphy

Alzheimer’s disease (AD) is the most relevant neurodegenerative disease. Worldwide, nearly 36 million people have Alzheimer’s or a related dementia which will double every 20 years to 115.4 million in 2050, and in Europe affects about 7.5 million people (75% of all dementia cases) and is expected to increase up to 10.5 million in 2030, with a reported prevalence rate of 6.2% for all those aged 60 years and over. Only 1-in-4 people with AD have been diagnosed. For the fast ageing populations of the Western societies, AD is becoming one of the main public health concerns, associated with a social and economic burden, and the provision of care for people with AD is a complex and costly issue. At present, there is not any therapy that can effectively cure the disease since it is a complex disorder of which the exact cause is still not known. The aproach to Alzheimer´s disease is changing gloabally. Oncovision’s plan, is to develop a new brain-dedicated PET that offers a valuable alternative to currently available whole-body PET systems. Caremibrain fulfils the necessities of neurologists and nuclear physicists regarding the β-amyloid radiotracers and the firsts true effective drugs against Alzheimer disease in its final development stage (Aducanumab –Biogen–; Azeliragon –Pfizer–; Gantenerumab –Roche–, Solanezumab –Eli Lilly–, Verubecestat –Merck–). Benefits High resolution and sensitivity More accurate diagnosis Lower radiotracer dose and greater patient comfort. Disease monitoring and treatment follow up.